Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 3/2012

01-06-2012

Serum Levels of Secreted Group IIA Phospholipase A2 in Benign Prostatic Hyperplasia and Prostate Cancer: A Biomarker for Inflammation or Neoplasia?

Authors: Mario Menschikowski, Albert Hagelgans, Susanne Fuessel, Olga A. Mareninova, Volker Neumeister, Manfred P. Wirth, Gabriele Siegert

Published in: Inflammation | Issue 3/2012

Login to get access

Abstract

Secreted group IIA phospholipase A2 (sPLA2-IIA) is markedly up-regulated in human prostate cancer (PCa) specimens and in some PCa-derived cell lines, indicating an important role of this enzyme in tumourigenesis. In this study, we measured levels of sPLA2-IIA, C-reactive protein (CRP), and prostate-specific antigen (PSA) in serum samples obtained from patients with benign prostatic hyperplasia (BPH) and with PCa of different stages. We found that serum levels of sPLA2-IIA and CRP in BPH and PCa patients were significantly elevated compared to those of healthy individuals, but the concentrations of these inflammatory biomarkers did not differ between patients with BPH or PCa. Furthermore, serum levels of sPLA2-IIA correlated with concentrations of CRP, but not with PSA, Gleason grade or tumour stage. In conclusion, these findings suggest that cancer-related changes are not exclusive factors contributing to elevated serum sPLA2-IIA levels and emphasize the utility of sPLA2-IIA as a circulating marker of inflammation in patients with BPH and PCa.
Literature
1.
Kaiser, E. 1999. Phospholipase A2: its usefulness in laboratory diagnostics. Critical Reviews in Clinical Laboratory Sciences 36: 65–163.PubMedCrossRef
2.
Nevalainen, T.J., M.M. Haapamäki, and J.M. Grönroos. 2000. Roles of secretory phospholipases A2 in inflammatory diseases and trauma. Biochimica et Biophysica Acta 1488: 83–90.PubMed
3.
Yamaguchi, O., K. Sugimura, K. Ishizuka, K. Suzuki, K. Hasegawa, K. Ohtsuka, T. Honma, and H. Asakura. 2002. Correlation between serum phospholipase A2 IIA levels and histological activity in patients with ulcerative colitis. International Journal of Colorectal Disease 17: 311–316.PubMedCrossRef
4.
Nevalainen, T.J. 1993. Serum phospholipases A2 in inflammatory diseases. Clinical Chemistry 39: 2453–2459.PubMed
5.
Menschikowski, M., A. Hagelgans, and G. Siegert. 2006. Secretory phospholipase A2 of group IIA: is it an offensive or a defensive player during atherosclerosis and other inflammatory diseases? Prostaglandins & Other Lipid Mediators 79: 1–33.CrossRef
6.
Triggiani, M., F. Granata, G. Giannattasio, and G. Marone. 2005. Secretory phospholipases A2 in inflammatory and allergic diseases: not just enzymes. The Journal of Allergy and Clinical Immunology 116: 1000–1006.PubMedCrossRef
7.
Scott, K.F., M. Sajinovic, J. Hein, S. Nixdorf, P. Galettis, W. Liauw, P. de Souza, Q. Dong, G.G. Graham, and P.J. Russell. 2010. Emerging roles for phospholipase A2 enzymes in cancer. Biochimie 92: 601–610.PubMedCrossRef
8.
Ogawa, M., S. Yamashita, K. Sakamoto, and S. Ikei. 1991. Elevation of serum group II. phospholipase A2 in patients with cancers of digestive organs. Research Communications in Chemical Pathology and Pharmacology 74: 241–244.PubMed
9.
Jemal, A., F. Bray, M.M. Center, J. Ferlay, E. Ward, and D. Forman. 2011. Global cancer statistics. CA: A Cancer Journal for Clinicians 61: 69–90.CrossRef
10.
Kilpeläinen, T.P., T.L. Tammela, M. Roobol, J. Hugosson, S. Ciatto, V. Nelen, S. Moss, L. Määttänen, and A. Auvinen. 2011. False-positive screening results in the European randomized study of screening for prostate cancer. European Journal of Cancer 18: 2698–2705.CrossRef
11.
Fitzpatrick, J.M., E. Banu, and S. Oudard. 2009. Prostate-specific antigen kinetics in localized and advanced prostate cancer. British Journal of Urology International 103: 578–587.CrossRef
12.
Stamey, T.A., M. Caldwell, J.E. McNeal, R. Nolley, M. Hemenez, and J. Downs. 2004. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? Journal of Urology 172: 1297–1301.PubMedCrossRef
13.
Beer, T.M., A.S. Lalani, S. Lee, M. Mori, K.M. Eilers, J.G. Curd, W.D. Henner, C.W. Ryan, P. Venner, J.D. Ruether, and K.N. Chi. 2008. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer 112: 2377–2383.PubMedCrossRef
14.
Heikkila, K., S. Ebrahim, and D.A. Lawlor. 2007. A systematic review of the association between circulating concentrations of C-reactive protein and cancer. Journal of Epidemiology and Community Health 61: 824–833.PubMedCrossRef
15.
Rintala, E.M., and T.J. Nevalainen. 1993. Synovial-type (group II) phospholipase A2 in serum of febrile patients with haematological malignancy. European Journal of Haematology 50: 11–16.PubMedCrossRef
16.
Nyman, K.M., W. Uhl, J. Forsström, M. Büchler, H.G. Beger, and T.J. Nevalainen. 1996. Serum phospholipase A2 in patients with multiple organ failure. Journal of Surgical Research 60: 7–14.PubMedCrossRef
17.
Dong, Z., Y. Liu, K.F. Scott, L. Levin, K. Gaitonde, R.B. Bracken, B. Burke, Q.J. Zhai, J. Wang, L. Oleksowicz, and S. Lu. 2010. Secretory phospholipase A2-IIa is involved in prostate cancer progression and may potentially serve as a biomarker for Prostate Cancer. Carcinogenesis 31: 1948–1955.PubMedCrossRef
18.
De Nunzio, C., G. Kramer, M. Marberger, R. Montironi, W. Nelson, F. Schröder, A. Sciarra, and A. Tubaro. 2011. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. European Urology 60: 106–117.PubMedCrossRef
19.
Sciarra, A., G. Mariotti, S. Salciccia, A.A. Gomez, S. Monti, V. Toscano, and F. Di Silverio. 2008. Prostate growth and inflammation. The Journal of Steroid Biochemistry and Molecular Biology 108: 254–260.PubMedCrossRef
20.
Crowl, R.M., T.J. Stoller, R.R. Conroy, and C.R. Stoner. 1991. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. Journal of Biological Chemistry 266: 2647–2651.PubMed
21.
De Marzo, A.M., E.A. Platz, S. Sutcliffe, J. Xu, H. Gronberg, C.G. Drake, Y. Nakai, W.B. Isaacs, and W.G. Nelson. 2007. Inflammation in prostate carcinogenesis. Nature Reviews. Cancer 7: 256–269.PubMedCrossRef
22.
Hanahan, D., and R.A. Weinberg. 2011. Hallmarks of cancer: the next generation. Cell 144: 646–674.PubMedCrossRef
23.
Grivennikov, S.I., F.R. Greten, and M. Karin. 2010. Immunity, inflammation, and cancer. Cell 140: 883–899.PubMedCrossRef
24.
Schenk, J.M., A.R. Kristal, M.L. Neuhouser, C.M. Tangen, E. White, D.W. Lin, M. Kratz, and I.M. Thompson. 2010. Biomarkers of systemic inflammation and risk of incident, symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. American Journal of Epidemiology 171: 571–582.PubMedCrossRef
25.
Heikkilä, K., R. Harris, G. Lowe, A. Rumley, J. Yarnell, J. Gallacher, Y. Ben-Shlomo, S. Ebrahim, and D.A. Lawlor. 2009. Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a metaanalysis. Cancer Causes & Control 20: 15–26.CrossRef
26.
Lehrer, S., E.J. Diamond, B. Mamkine, M.J. Droller, N.N. Stone, and R.G. Stock. 2005. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer. BJU International 95: 961–962.PubMedCrossRef
27.
Heikkilä, K., S. Ebrahim, and D.A. Lawlor. 2008. Systematic review of the association between circulating interleukin-6 (IL-6) and cancer. European Journal of Cancer 44: 937–945.PubMedCrossRef
28.
Baillargeon, J., E.A. Platz, D.P. Rose, B.H. Pollock, D.P. Ankerst, S. Haffner, B. Higgins, A. Lokshin, D. Troyer, J. Hernandez, S. Lynch, R.J. Leach, and I.M. Thompson. 2006. Obesity, adipokines, and prostate cancer in a prospective populationbased study. Cancer Epidemiology, Biomarkers & Prevention 15: 1331–1335.CrossRef
29.
Il’yasova, D., L.H. Colbert, T.B. Harris, A.B. Newman, D.C. Bauer, S. Satterfield, and S.B. Kritchevsky. 2005. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiology, Biomarkers & Prevention 14: 2413–2418.CrossRef
30.
Laye, J.P., and J.H. Gill. 2003. Phospholipase A2 expression in tumours: a target for therapeutic intervention? Drug Discovery Today 8: 710–716.PubMedCrossRef
31.
Nagy, B., A. Szendroi, and I. Romics. 2009. Overexpression of CD24, c-myc and phospholipase 2A in prostate cancer tissue samples obtained by needle biopsy. Pathology and Oncology Research 15: 279–283.PubMedCrossRef
32.
Kallajoki, M., K.A. Alanen, M. Nevalainen, and T.J. Nevalainen. 1998. Group II. phospholipase A2 in human male reproductive organs and genital tumours. Prostate 35: 263–272.PubMedCrossRef
33.
Graff, J.R., B.W. Konicek, J.A. Deddens, M. Chedid, B.M. Hurst, B. Colligan, B.L. Neubauer, H.W. Carter, and J.H. Carter. 2001. Expression of group IIa secretory phospholipase A2 increases with prostate tumour grade. Clinical Cancer Research 7: 3857–3861.PubMed
34.
Jiang, J., B.L. Neubauer, J.R. Graff, M. Chedid, J.E. Thomas, N.W. Roehm, S. Zhang, G.J. Eckert, M.O. Koch, J.N. Eble, and L. Cheng. 2002. Expression of group IIA secretory phospholipase A2 is elevated in prostatic intraepithelial neoplasia and adenocarcinoma. The American Journal of Pathology 160: 667–671.PubMedCrossRef
35.
Sved, P., K.F. Scott, D. McLeod, N.J. King, J. Singh, T. Tsatralis, B. Nikolov, J. Boulas, L. Nallan, M.H. Gelb, M. Sajinovic, G.G. Graham, P.J. Russell, and Q. Dong. 2004. Oncogenic action of secreted phospholipase A2 in prostate cancer. Cancer Research 64: 6934–6940.PubMedCrossRef
36.
Kojima, S., D.J. Mulholland, S. Ettinger, L. Fazli, C.C. Nelson, and M.E. Gleave. 2006. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models. Prostate 66: 971–986.PubMedCrossRef
37.
Menschikowski, M., A. Hagelgans, E. Gussakovsky, H. Kostka, E.L. Paley, and G. Siegert. 2008. Differential expression of secretory phospholipases A2 in normal and malignant prostate cell lines: regulation by cytokines, cell signaling pathways, and epigenetic mechanisms. Neoplasia 10: 279–286.PubMed
38.
Mirtti, T., V.J.O. Laine, H. Hiekkanen, S. Hurme, O. Rowe, T.J. Nevalainen, M. Kallajoki, and K. Alanen. 2009. Group IIA phospholipase A2 as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality. Acta Pathologica, Microbiologica, et Immunologica Scandinavica 117: 151–161.PubMedCrossRef
39.
Ogawa, M., N. Sato, S. Endo, M. Kojika, Y. Yaegashi, Y. Kimura, K. Ikeda, and T. Iwaya. 2005. Group IIA-soluble phospholipase A2 levels in patients with infections after esophageal cancer surgery. Surgery Today 35: 912–918.PubMedCrossRef
40.
Mallat, Z., J. Benessiano, T. Simon, S. Ederhy, C. Sebella-Arguelles, A. Cohen, V. Huart, N.J. Wareham, R. Luben, K.T. Khaw, A. Tedgui, and S.M. Boekholdt. 2007. Circulating secretory phospholipase A2 activity and risk of incident coronary events in healthy men and women: the EPIC-Norfolk study. Arteriosclerosis, Thrombosis, and Vascular Biology 27: 1177–1183.PubMedCrossRef
Metadata
Title
Serum Levels of Secreted Group IIA Phospholipase A2 in Benign Prostatic Hyperplasia and Prostate Cancer: A Biomarker for Inflammation or Neoplasia?
Authors
Mario Menschikowski
Albert Hagelgans
Susanne Fuessel
Olga A. Mareninova
Volker Neumeister
Manfred P. Wirth
Gabriele Siegert
Publication date
01-06-2012
Publisher
Springer US
Published in
Inflammation / Issue 3/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-011-9418-1

Other articles of this Issue 3/2012

Inflammation 3/2012 Go to the issue

OriginalPaper

Clinical Usefulness of Multiplex PCR Lateral Flow in MRSA Detection: A Novel, Rapid Genetic Testing Method

OriginalPaper

Fractalkine Upregulates Inflammation through CX3CR1 and the Jak–Stat Pathway in Severe Acute Pancreatitis Rat Model

OriginalPaper

Acute Oxidative Stress Affects IL-8 and TNF-α Expression in IPEC-J2 Porcine Epithelial Cells

OriginalPaper

Effect of HSP65 on the Expression of Adhesion Molecules in Mice Heart Endothelial Cells

OriginalPaper

Berberine Ameliorates Pro-inflammatory Cytokine-Induced Endoplasmic Reticulum Stress in Human Intestinal Epithelial Cells In Vitro

OriginalPaper

Mast-Cell-Releasing Tryptase Triggers Acute Lung Injury Induced by Small Intestinal Ischemia–Reperfusion by Activating PAR-2 in Rats
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits